A detailed history of Bank Of America Corp transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 221,327 shares of NRIX stock, worth $5.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
221,327
Previous 97,176 127.76%
Holding current value
$5.98 Million
Previous $1.43 Million 223.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.02 - $21.3 $1.49 Million - $2.64 Million
124,151 Added 127.76%
221,327 $4.62 Million
Q1 2024

May 15, 2024

BUY
$7.77 - $15.66 $607,924 - $1.23 Million
78,240 Added 413.18%
97,176 $1.43 Million
Q4 2023

Feb 14, 2024

SELL
$4.25 - $10.71 $2.42 Million - $6.09 Million
-569,089 Reduced 96.78%
18,936 $195,000
Q2 2023

Aug 14, 2023

SELL
$8.7 - $13.28 $375,657 - $573,417
-43,179 Reduced 6.84%
588,025 $5.87 Million
Q1 2023

May 12, 2023

SELL
$8.56 - $13.26 $773,267 - $1.2 Million
-90,335 Reduced 12.52%
631,204 $5.61 Million
Q4 2022

Feb 10, 2023

BUY
$9.86 - $14.59 $5.83 Million - $8.63 Million
591,198 Added 453.58%
721,539 $7.92 Million
Q3 2022

Nov 14, 2022

BUY
$12.33 - $19.81 $524,357 - $842,459
42,527 Added 48.43%
130,341 $1.7 Million
Q2 2022

Aug 12, 2022

BUY
$7.88 - $14.82 $277,880 - $522,612
35,264 Added 67.11%
87,814 $1.11 Million
Q1 2022

May 16, 2022

SELL
$12.94 - $29.65 $465,387 - $1.07 Million
-35,965 Reduced 40.63%
52,550 $736,000
Q4 2021

Feb 08, 2022

BUY
$26.43 - $34.5 $355,298 - $463,783
13,443 Added 17.91%
88,515 $2.56 Million
Q3 2021

Nov 15, 2021

BUY
$22.71 - $36.69 $1.07 Million - $1.73 Million
47,163 Added 168.99%
75,072 $2.25 Million
Q2 2021

Sep 13, 2021

BUY
$24.21 - $35.89 $675,676 - $1 Million
27,909 New
27,909 $740,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.27B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.